Public procurement notice: Contract Award Notice
Published: 2022-07-08
Buyer: Indivumed GmbH
Country: DE
Contract type: Services
Procedure: Competitive procedure with negotiation
CPV classification: 73000000 | 73100000 | 73111000 | 73200000 | 73300000
Estimated value: 215000 EUR
Award criteria: The most economic tender
EU fund: ERDF

Technical requirements: Indivumed, founded in 2001 and operational since 2002, is an internationally oriented biotechnology company in the field of "digital health" and personalized oncology with headquarters in Hamburg. Indivumed employs approximately 240 people worldwide, of which approximately 190 are based in Hamburg.
Indivumed's goal is to decipher cancer diseases in order to develop new active agents and diagnostic procedures for targeted ("personalized") cancer therapy. In this respect, Indivumed is fundamentally different from other biotechnology and biopharmaceutical companies, as it has a unique development platform that has been systematically built up over the past 15 years. Thanks to the rapid development of cost-effective and highly sensitive tissue analysis methods in combination with complex computer technologies (cloud solutions) and data analysis methods (e.g. artificial intelligence), Indivumed is now able to use its existing sample bank and clinical network for AI-assisted drug development.
This project will generate a unique platform for rapid and efficient therapeutic target discovery with an aim to driving therapeutic development programs. This platform combines Indivumed's established clinical network, AI-driven oncology analytics, and state-of-the-art disease models for therapeutic target validation to develop new drugs in the shortest possible time.
Cryopreserved tissue samples from up to 10 selected entities (CRC, NSCLC, breast cancer, gastric cancer, liver cancer, kidney cancer, ovary cancer, prostate cancer, bladder cancer, pancreatic cancer) will be provided as source material for complex cellular model generation. These cohorts will be extended with up to 3 types of tissue that have been neoadjuvantly treated. Optimized protocols, complex media and matrix compositions for the needs of each entity should be considered to achieve the highest success ratio for cellular model generation.
After generation of the patient derived models, siRNA/shRNA mediated reduction of specific (yet to be defined) gene targets is planned. Experimental set-up should be designed to deal with multiple targets in several disease models in parallel, including appropriate controls and phenotypic readouts.
Regarding the legal aspects, Indivumed requires full and unrestricted scientific and commercial freedom to operate with regard to all generated organoids and results of their respective genetic manipulation, including to their licensing and/or sale to third parties. The applicant should provide overview about own patents or possibly touched patents of other companies.
Further explanations of the points mentioned there are described in detail in the specifications. The specifications and further procurement documents (also the contract) will be issued after the conclusion of the prior competition, but only if the applicant has submitted the Non-Disclosure Agreement (see Application Forms) with his/her application.
Pursuant to § 14 Para. 4 no. 5, no. 9 VgV (Procurement Ordinance - Vergabeverordnung), the right is reserved to award the repetition of similar services and deliveries corresponding to the basic project in a negotiated procedure without a competitive tender under the same conditions as the basic contract.
European Regional Development Fund (ERDF): "Investitionen in Wachstum und Beschäftigung" für das Land Hamburg in Deutschland (CCI 2014DE16RFOP006) Version 3.0.
Referring to section II.2.10: variant tenders (variation/alternative tenders) are the subject of the negotiated procedure. The right to exclude variant tenders is reserved. For further details, please refer to the procurement documents.
With regard to no. II.1.7 and V.2.4: The estimated contract value exceeds the applicable threshold of EUR 215,000.00.
- Sec. 134 Para. 2 GWB - Duty to inform and wait: A contract may not be concluded until 15 calendar days after the information pursuant to Sec. 134 Para. 1 GWB has been sent. If the information is sent electronically or by fax, the period is reduced to 10 calendar days. The time limit begins on the day after the information is sent by the contracting authority; the day of receipt by the tenderer and candidate concerned is irrelevant.
1) the applicant became aware of the alleged violation of provisions governing the awarding of public contracts before submitting the appeal and did not object to the contracting entity within 10 calendar days; the deadline stipulated in Sec. 134 Para. 2 GWB remains unaffected;
2) violations of provisions governing the awarding of public contracts which become apparent from the tender notice are not notified to the contracting entity by the end of the period specified in the notice for the submission of a tender or application;
3) violations of provisions governing the awarding of public contracts which only become apparent from the award documents are not notified to the contracting entity by the end of the period specified in the notice for the submission of a tender or application;


Winner: CELLphenomics GmbH
Award value: 215000
Number of bids: 1